Drug Profile
Fenofibrate - Veloxis Pharmaceuticals
Alternative Names: Fenoglide; LCP-FenoCholLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator LifeCycle Pharma
- Developer Veloxis Pharmaceuticals
- Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hyperlipidaemia
Most Recent Events
- 03 Mar 2020 Veloxis Pharmaceuticals has been acquired by Asahi Kasei
- 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
- 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals